Efficacy of Nrf2 activation in a proteinuric Alport syndrome mouse model
Open Access
- 17 June 2025
- journal article
- Published by Life Science Alliance, LLC in Life Science Alliance
- Vol. 8 (8) , e202503330
Abstract
Activation of nuclear factor erythroid 2–related factor 2 (Nrf2) has shown protective effects in experimental models of acute kidney injury and nonproteinuric chronic kidney disease. However, the efficacy of Nrf2 activation for proteinuric chronic kidney disease with glomerular injury is controversial, as a transient increase in proteinuria is observed. Here, we identified a potent Nrf2 activator UD-051, which inhibits the interaction between Kelch-like ECH-associated protein 1 (Keap1) and Nrf2. UD-051 significantly ameliorated the progressive phenotype of Alport syndrome mouse model in an Nrf2-dependent manner, accompanied by increased proteinuria. Mild Nrf2 activation by geneticKeap1knockdown or pharmacological Keap1 inhibition with CDDO-imidazolide did not attenuate Alport kidney disease, suggesting that strong Nrf2 activation is essential for clear therapeutic efficacy. In-depth analysis revealed that UD-051 suppressed tubular injury, including oxidative stress, inflammation, and dysregulated metabolism. UD-051 with losartan, a renin–angiotensin system inhibitor that targets glomerular dysfunction, vastly ameliorated Alport kidney disease. Our study provides a comprehensive insight into the efficacy of Nrf2 activation in Alport syndrome and provides a rationale for adding a Keap1-Nrf2 interaction inhibitor to a renin–angiotensin system inhibitor.Keywords
Funding Information
- Japan Agency for Medical Research and Development (23ek0310017h0003)
- MEXT | Japan Society for the Promotion of Science (JP23K14358)
- MEXT | Japan Society for the Promotion of Science (JP22H02810)
- MEXT | Japan Society for the Promotion of Science (JP23K06165)
- Wellcome Trust Senior Fellowship (202860/Z/16/Z)
This publication has 50 references indexed in Scilit:
- CDDO-Me ameliorates podocyte injury through anti-oxidative stress and regulation of actin cytoskeleton in adriamycin nephropathyBiomedicine & Pharmacotherapy, 2023
- A web-based integrative transcriptome analysis, RNAseqChef, uncovers the cell/tissue type-dependent action of sulforaphaneJournal of Biological Chemistry, 2023
- Advanced oxidation protein products contribute to chronic kidney disease‐induced muscle atrophy by inducing oxidative stress via CD36/NADPH oxidase pathwayJournal of Cachexia, Sarcopenia and Muscle, 2021
- Effect of bardoxolone methyl on the urine albumin-to-creatinine ratio in patients with type 2 diabetes and stage 4 chronic kidney diseaseKidney International, 2019
- Megalin and cubilin in proximal tubule protein reabsorption: from experimental models to human diseaseKidney International, 2016
- The emerging role of Nrf2 in mitochondrial functionFree Radical Biology and Medicine, 2015
- Dose-dependent deleterious and salutary actions of the Nrf2 inducer dh404 in chronic kidney diseaseFree Radical Biology and Medicine, 2015
- Prevention of Murine Lupus Nephritis by Targeting Multiple Signaling Axes and Oxidative Stress Using a Synthetic TriterpenoidArthritis & Rheumatology, 2014
- Hepatocyte-specific deletion of the keap1 gene activates Nrf2 and confers potent resistance against acute drug toxicityBiochemical and Biophysical Research Communications, 2006
- Direct measurement of NAD(P)H:quinone reductase from cells cultured in microtiter wells: A screening assay for anticarcinogenic enzyme inducersAnalytical Biochemistry, 1988